Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The influenza virus neuraminidase (NA) is a major surface glycoprotein found on the envelope of influenza viruses. It plays a critical role in the viral life cycle, particularly in the release of newly formed virions from infected host cells and in preventing aggregation of virions by removing sialic acid residues from glycoproteins. NA acts as an exosialidase (EC 3.2.1.18), cleaving α-ketosidic linkages between terminal sialic acid residues and adjacent sugars on glycoproteins or glycolipids. Neuraminidase inhibitors such as oseltamivir, zanamivir, and peramivir are clinically used antivirals that block NA activity.
Neuraminidase inhibition; blocks the activity of neuraminidase, preventing the release of newly formed virions from infected host cells and limiting virus spread.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza virus neuraminidase antigen (None).